Statement of Principles concerning toxic retinopathy (Balance of Probabilities) (No. 20 of 2018)

The central concept is "toxic retinopathy" as defined in section 7(2). It is not a single disease label but a category encompassing pathological changes in retinal cells caused by a chemical agent, provided there is sustained vision impairment and evidence connecting the changes to a chemical agent. The definition excludes common causes of vision loss in older veterans such as macular degeneration and retinal detachment, which have their own separate SoPs. The instrument then lists 16 specific exposure factors (section 9) that are deemed sufficient, if present and related to service, to connect the condition to service on the balance of probabilities. These factors are tightly defined with dose, duration, and route of administration thresholds. For example, quinoline-based drug exposure requires either six months of daily chloroquine, a cumulative dose of 200 grams, five years of daily hydroxychloroquine, or 400 grams cumulative hydroxychloroquine. Tamoxifen requires six months daily or 100 grams cumulative. Intravitreal aminoglycosides (amikacin or gentamicin) require exposure within seven days before clinical onset. Other factors include fomivirsen, deferoxamine (intravenous or subcutaneous), phenothiazines (chlorpromazine, thioridazine) for at least two weeks, clofazimine for three months, ritonavir for three months, interferon for four weeks, oral canthaxanthin supplements (one year or 15 grams cumulative), inhaled isopropyl nitrite within two weeks, and intravenous talc-containing drugs within two years. Two factors apply only to cystoid macular oedema: daily niacin at 1.5 grams for two weeks or intravenous paclitaxel/docetaxel within three months, and topical adrenaline in aphakic or pseudophakic eyes. A catch-all factor (16) is inability to obtain appropriate clinical management, but this applies only to material contribution or aggravation, not initial onset. The instrument also defines "relevant service" narrowly to mean eligible war service (other than operational service), defence service (other than hazardous and British nuclear test defence service) under VEA, or peacetime service under MRCA. This means veterans with operational service (active combat) or hazardous service cannot use this SoP; they must rely on the reasonable hypothesis standard under different provisions. The instrument also cross-references other SoPs via section 11: if a factor refers to an injury or disease covered by another SoP (e.g., if a drug causes another condition that then causes retinopathy), then the factors of that other SoP apply. This is important for cascading causation scenarios.

The primary affected group is veterans and members of the Australian Defence Force who have rendered "relevant service" as defined in the dictionary: eligible war service (non-operational), defence service (non-hazardous and non-British nuclear test), and peacetime service under MRCA. This excludes the majority of veterans who served in operational theatres or hazardous environments, who instead rely on the reasonable hypothesis standard under separate SoPs or direct provisions. For those within scope, the SoP affects their ability to establish a causal link for toxic retinopathy without needing to produce independent epidemiological or toxicological evidence; they need only prove one of the listed exposures occurred during their service. The instrument also affects the Repatriation Commission and the Military Rehabilitation and Compensation Commission as decision-makers, who must apply these factors when assessing claims. The SoP indirectly affects healthcare providers within the Defence Force and the Department of Veterans' Affairs (DVA) who prescribe or administer the listed drugs. For example, a defence force doctor prescribing chloroquine for malaria prophylaxis or hydroxychloroquine for autoimmune conditions must be aware that long-term use could generate a compensable condition under this SoP. This may alter prescribing patterns or increase documentation requirements. Pharmaceutical companies that manufacture or supply the listed drugs may see increased compensation liability, though the effect is diffuse because the toxic retinopathy must be service-related. The instrument also affects DVA's internal guidelines and the AAT's review process, as the SoP provides a structured framework for evaluating these claims. Claimants' legal representatives will use the SoP to frame their arguments, particularly the precise definitions of dose and duration. The exclusion of common age-related conditions such as macular degeneration means that many veterans with vision loss will not qualify under this SoP unless a specific chemical exposure can be demonstrated. The instrument does not affect veterans with operational service; they have a lower evidentiary burden (reasonable hypothesis) and may rely on this SoP as persuasive but not binding. However, the RMA intends the SoP to apply only to the balance of probabilities standard, so it is not a substitute for the operational service framework.

The instrument creates no direct duties on individuals; it is an evidentiary standard applied by decision-makers. The key duty is on the Repatriation Commission and the MRCA Commission to apply the SoP correctly when determining claims under the balance of probabilities standard. They must assess whether at least one of the factors in section 9 exists and whether that factor is related to the person's relevant service as required by section 10(1). The factor must have occurred during or be causally connected to the service, not just generally in the person's life. For factor 16 (inability to obtain appropriate clinical management), section 10(2) imposes an additional limitation: it applies only to material contribution or aggravation of toxic retinopathy where the condition was suffered or contracted before or during (but not arising out of) the person's relevant service. This prevents the factor being used for initial onset if the condition already existed before service. Claimants have the right to rely on the SoP to simplify their case. They do not need to prove general causation; they only need to show that one of the specific exposures occurred and that the exposure is related to service. However, the right is conditional on meeting the precise thresholds. For example, if a veteran took hydroxychloroquine for four years and nine months, the threshold of five years is not met, and the claim would fail under that factor (unless the cumulative dose of 400 grams was reached earlier). The definition of "being treated with a quinoline-based drug as specified" sets out four alternative paths, each with strict time or dose requirements. Similarly, tamoxifen requires six months or 100 grams, and canthaxanthin requires one year or 15 grams. Claimants have the right to rely on medical evidence confirming the diagnosis of toxic retinopathy per section 7(2), including evidence that the pathological changes are caused by a chemical agent and that vision impairment is sustained. The dictionary definition requires that the pathological changes be "caused by a chemical agent" based on history, examination or diagnostic testing. This imposes a diagnostic duty on ophthalmologists to document the chemical causation, which may be challenging if multiple potential causes exist. For death claims, the definition of terminal event in the dictionary lists proximate causes such as pneumonia, respiratory failure, and cardiac arrest, and the retinopathy must have contributed to that event. Claimants bear the onus of proving the factor existed and related to service, but the SoP reduces the onus on general causation. The instrument also cross-references other SoPs under section 11, which means if a factor refers to another injury or disease (for instance, if the chemical agent first causes a condition covered by a different SoP), the factors from that other SoP also must be satisfied. This creates a duty for decision-makers to check the relevant SoP for each referenced condition.

This instrument does not itself impose penalties. It is a legislative instrument made by the RMA under statutory authority, and it operates within the broader claims and review framework of the VEA and MRCA. Penalties may arise under the VEA or MRCA for fraudulent claims or statements, not under this SoP. For example, a false or misleading statement in a claim to establish a factor could attract penalties under the Criminal Code or specific provisions of the VEA (such as section 56A or similar). The SoP's role is evidentiary; if a claimant attempts to rely on an exposure that did not occur, and the Commission finds that the factor does not exist, the claim will be rejected. There is no penalty for an unsuccessful claim per se. Enforcement of the SoP is through the administrative decision-making process: the Repatriation Commission must apply it, and if it fails to do so, the claimant can seek merits review at the Veterans' Review Board (VRB) and then the Administrative Appeals Tribunal (AAT). The AAT may set aside a decision that incorrectly applied the SoP, for instance by misinterpreting a definition or overlooking an applicable factor. The instrument's definitions are legally binding on decision-makers; failure to apply them correctly is an error of law. Judicial review in the Federal Court is available on questions of law, such as whether the RMA exceeded its power under section 196B(3) or whether a particular factor was properly interpreted. However, the source does not record any litigation. The SoP also interacts with the criminal law if there is evidence that a person knowingly provided false information to support a factor, potentially constituting an offence under the Criminal Code (e.g., obtaining a financial advantage by deception). For example, falsely claiming to have taken a cumulative dose of 400 grams of hydroxychloroquine could lead to prosecution. But such penalties arise from the underlying Acts, not from this instrument. The instrument's revocation of the 2009 SoP means that any claims relying on the old SoP after 2 April 2018 are invalid; decision-makers must use this version. Failure to do so could be an error. The SoP does not have any direct enforcement mechanism against prescribers or drug manufacturers; it merely sets out the evidentiary factors for compensation. However, it could indirectly affect prescribing behaviour if doctors become concerned that long-term prescriptions of chloroquine or hydroxychloroquine will lead to compensable conditions. That is a behavioural consequence, not a penalty.

The instrument is made under subsection 196B(3) of the VEA, which grants the RMA power to determine SoPs for the purposes of claims under the VEA and, by cross-reference, the MRCA (section 339 of the MRCA). It revokes SoP No. 40 of 2009 concerning toxic maculopathy, which had a narrower scope. The new SoP expands the condition to toxic retinopathy, including additional subtypes and factors. It also interacts with other SoPs via section 11: if a factor in this SoP refers to an injury or disease that is covered by another SoP, then the factors in that other SoP must also be satisfied. This is important for cascading conditions. For example, if a factor refers to "renal disease" and there is an SoP for renal disease, the claimant must meet the factors of that SoP. The source does not list specific cross-references, but the principle is that the SoP does not operate in isolation. The instrument also interacts with the therapeutic goods regime: the listed drugs are all approved for use in Australia, but the SoP does not alter their regulatory status. It does, however, create a financial liability for the Commonwealth if a claim succeeds, which may influence government decisions about funding or guidelines for these drugs. The SoP applies to claims under section 120B of the VEA and section 339 of the MRCA, which govern claims where the standard of proof is the balance of probabilities. Claims for operational service under VEA (section 120) use the reasonable hypothesis standard, and this SoP is not directly applicable, though it may be used as evidence of a possible connection. For hazardous service and British nuclear test defence service, different provisions apply, and those claims are excluded from the definition of "relevant service" in this SoP. The instrument also interacts with the common law of evidence, but in practice it displaces it within the claims system: the SoP provides a structured list of factors that are deemed sufficient, and decision-makers may not disregard them without good medical-scientific grounds. The Veterans' Entitlements Act itself sets out the hierarchy of SoPs, and this instrument is a subordinate legislative instrument. If there is a conflict between this SoP and the VEA or MRCA, the primary Acts prevail. The dictionary in Schedule 1 defines "relevant service" by reference to the VEA and MRCA, so the SoP's scope is tied to those Acts. The note that "being treated with a quinoline-based drug as specified" includes definitions referencing specific durations and doses, which must be interpreted in accordance with ordinary principles of statutory interpretation. The exclusion of canthaxanthin used as a colour additive in foods or drugs means that dietary sources of canthaxanthin (such as in some salmon or pills) are not captured unless they meet the specified supplement criteria.

The instrument is a new SoP that commences on 2 April 2018 and revokes the earlier Statement of Principles concerning toxic maculopathy No. 40 of 2009 made under the same head of power. That earlier SoP was limited to toxic maculopathy, which is a subtype of retinopathy affecting the macula. The new instrument broadens the scope to toxic retinopathy, which includes chemically induced chronic cystoid macular oedema, crystalline retinopathy, and peripheral retinal degeneration that does not involve the macula, in addition to toxic maculopathy. The definitions of drug exposures have been updated and expanded. For example, the 2009 SoP may have had different thresholds or a different list of drugs. The source does not provide the text of the revoked SoP, so a detailed comparison is not possible. However, the revocation is significant because claims for toxic maculopathy made after 2 April 2018 must be assessed under the new SoP. If a claimant has a condition that falls under the old definition of toxic maculopathy but not under the new definition of toxic retinopathy (for example, if the new definition adds additional exclusions), the claimant may need to rely on a different SoP or on general causation evidence. The instrument also appears to have replaced the old factor list; for instance, the new SoP includes factors for niacin, paclitaxel, docetaxel, topical adrenaline, and fomivirsen that may not have been in the 2009 SoP. The dictionary definitions have also been refined. The note regarding canthaxanthin is new: it explicitly excludes canthaxanthin used as a colour additive in foods or drugs, which suggests that the old SoP may not have had that exclusion or had a different definition. The instrument does not have any later amendments recorded in the source; it is the original version. However, as a legislative instrument, it may be subsequently amended or revoked by a later SoP. Practitioners should check the current Federal Register of Legislation for any amendments after 2018. The instrument replaces SoP No. 40 of 2009 but does not purport to revoke any other SoPs. It is self-contained. The basis for the factors (section 8) is the RMA's view that, on sound medical-scientific evidence, it is more probable than not that toxic retinopathy and death from toxic retinopathy can be related to relevant service. This represents the RMA's assessment of the current state of evidence, and future amendments could follow changes in medical understanding.

The source does not name any cases. However, the instrument is of a type that is frequently the subject of merits review and judicial review in Australia. SoPs under the VEA are regularly considered by the Veterans' Review Board (VRB), the Administrative Appeals Tribunal (AAT), and the Federal Court. The specificity of the definitions in this SoP is likely to generate disputes over interpretation. For example, the meaning of "continuous period" in the drug definitions (e.g., six months of daily chloroquine) could be litigated: does a break of a few days break the continuity? The cumulative dose thresholds also invite evidentiary arguments about whether the claimant actually ingested 200 grams of chloroquine or 400 grams of hydroxychloroquine, especially if records are incomplete. The definition of "toxic retinopathy" itself may be contested: whether the pathological changes are "caused by a chemical agent" requires expert evidence, and the exclusion of macular degeneration may be disputed if macular degeneration is present but a chemical contribution is alleged. The definition of "cystoid macular oedema" carries its own medical nuances, and the factors specific to that subtype (niacin and paclitaxel/docetaxel) may be challenged if the oedema is not clearly of the type defined. Factor 16 (inability to obtain appropriate clinical management) is a broad factor that could be misused; its limitation to material contribution or aggravation is a safeguard, but what constitutes "inability" may be litigated. The interaction with other SoPs under section 11 could create cascading litigation: if a factor refers to a disease that has its own SoP, the claimant must meet the factors of that SoP, which may themselves be complex. The AAT has frequently considered the construction of SoP factors, often applying a strict textual approach. The instrument's balance of probabilities standard means that claimants must prove the factor on the balance of probabilities, not beyond reasonable doubt. This may reduce the evidentiary threshold but still requires sufficient proof. In practice, many veterans with non-operational service have difficulty proving specific drug exposures decades earlier, especially if the records have been destroyed. The litigation history of similar SoPs suggests that the AAT is willing to accept lay evidence if consistent with medical documentation, but the cumulative dose thresholds may be hard to prove without contemporaneous records. No reported superior court judgments specifically on this instrument are known, but the Federal Court has considered other SoPs, often deferring to the RMA's medical-scientific judgment unless the SoP is irrational or beyond power.

Several traps in this instrument can catch unwary claimants and practitioners. First, the definition of "relevant service" is narrower than many assume. It excludes operational service (active combat), hazardous service (e.g., nuclear testing, bomb disposal), and British nuclear test defence service. This means veterans with war service in Vietnam, Iraq, or Afghanistan (classified as operational) cannot use this SoP for their claims; they must apply under the reasonable hypothesis standard, where this SoP may be persuasive but is not binding. Second, the factors require precise dose and duration thresholds. For instance, being treated with a quinoline-based drug as specified requires either six months of daily chloroquine or 200 grams cumulative. If a veteran took chloroquine for five months and three weeks, they fail the continuous period requirement. The cumulative dose must be proven, which may be impossible if records are lost. Third, the exclusion of certain conditions from the definition of toxic retinopathy is critical: the instrument excludes toxic optic neuropathy, macular degeneration, retinal detachment and breaks, and retinal photodamage. A veteran with vision loss from macular degeneration cannot claim under this SoP unless they also have a distinct chemical retinopathy. Fourth, the factor for cystoid macular oedema under topical adrenaline in an aphakic or pseudophakic eye applies only to that subtype and only in eyes without a natural lens or with an intraocular lens. This is a very specific scenario. Fifth, factor 16 (inability to obtain appropriate clinical management) is limited to material contribution or aggravation of existing retinopathy; it cannot be used for initial onset. It also requires that the inability to obtain management was related to service. This factor may be difficult to prove because what constitutes "appropriate" clinical management is not defined. Sixth, the dictionary definition of "being treated with tamoxifen as specified" requires six months or 100 grams, but tamoxifen is often given for shorter periods or at different dosages. The same applies to other drugs. Seventh, the exclusion of canthaxanthin used as a colour additive means that dietary supplements (e.g., tanning pills) are covered only if they meet the specified thresholds, but food colouring is excluded. This could be overlooked. Eighth, the instrument applies only to claims under section 120B of VEA or section 339 of MRCA; it does not apply to section 120 (operational service) or other MRCA sections. If a claim is mistakenly assessed under the wrong provision, the SoP may be misapplied. Ninth, the relationship requirement in section 10(1) means the factor must be related to relevant service. If the drug was prescribed by a civilian doctor after service, it must still be causally connected to service (e.g., because the underlying condition requiring the drug was service-related). This is an additional hurdle. Tenth, the cross-reference in section 11 to other SoPs can create a chain of requirements that may be overlooked. If a factor refers to an injury or disease covered by another SoP (for example, if the toxic retinopathy was caused by a drug that first caused a condition covered by a different SoP), the factors of that other SoP must also be satisfied. This may multiply the evidentiary burden.

Compliance with this instrument is not a direct legal obligation for individuals; rather, it is a framework that must be correctly applied by decision-makers and used by claimants to establish their cases. For a veteran or former member of the Forces who may have a claim for toxic retinopathy, the practical steps are as follows. First, obtain a definitive medical diagnosis from an ophthalmologist confirming toxic retinopathy as defined by section 7(2). The diagnosis must include evidence of sustained vision impairment and evidence that the pathological changes are caused by a chemical agent. The clinician should document the history of chemical exposure, noting the specific agent, dose, duration, and route. Second, identify which of the 16 factors in section 9 may apply. Gather all service and medical records showing the prescription, administration, or use of any of the listed drugs or substances. For quinoline-based drugs, record the start and end dates of treatment and the cumulative dose. For tamoxifen, document the period and cumulative dose. For intravitreal aminoglycosides, obtain records of the injection and the specific drug (amikacin or gentamicin). For other factors, ensure the timing matches the windows specified (e.g., within seven days before clinical onset for aminoglycosides). Third, ensure that the factor is related to relevant service as defined in the dictionary. The relevant service is non-operational war service, defence service (non-hazardous), or peacetime service under MRCA. If the drug was prescribed during service or as a result of a service-related condition, that satisfies the relationship. Fourth, for factor 16 (inability to obtain appropriate clinical management), confirm that the retinopathy existed before or during service (but did not arise out of service) and that the inability to obtain management materially contributed to or aggravated the condition. This may require evidence of medical records showing that management was unavailable or inaccessible due to service circumstances. Fifth, if the factor refers to another injury or disease that is covered by another SoP (for example, if the chemical agent caused an intermediate condition), identify that SoP and ensure its factors are also satisfied. Sixth, for death claims, ensure that the terminal event (pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function) was contributed to by the toxic retinopathy. Seventh, for decision-makers in the Repatriation Commission or MRCA Commission, apply the SoP strictly. Verify that the diagnosis meets the definition, that the factor exists on the balance of probabilities, and that the factor is related to relevant service. Do not accept a claim if the drug exposure does not meet the precise thresholds, even if the clinical picture is consistent. Maintain a checklist of each factor's requirements. Eighth, for legal practitioners representing claimants, prepare a detailed submission mapping the evidence to each element of the relevant factor. Use the dictionary definitions to frame arguments. Be prepared to argue over interpretation of "continuous period" and "cumulative dose" if records are incomplete. Ninth, for clinicians prescribing the listed drugs to service personnel, maintain meticulous records of the indication, dose, frequency, and duration of treatment. Advise patients of potential retinal side effects and offer regular eye examinations where appropriate, especially for chronic use of chloroquine, hydroxychloroquine, tamoxifen, and clofazimine. This may reduce the risk of severe retinopathy and also generate documentary evidence if a claim later arises. Tenth, for all parties, note the commencement date of 2 April 2018. Claims assessed before that date would have been under the revoked SoP No. 40 of 2009. For claims after that date, this instrument is the governing standard.